

Chair (SAPA-NE): Liqiang Derek Tou

Co-Chairs (SAPA-NE): Xiang Niu.

Organizing committee:

Mark Lin, Xiaotian Zhong, Bingli Ma, Daming Gou, Derek Tou, Dongli Chen, George Li, Hou Li, Huimin Chen, Jenny Li, Jinhua Zhang, Jun Zhao, Kechun Li, Qing Huang, Weijun Ma, Wenge Wang, Qingcong Lin, Min Chen, Nianding Zhang, Tianxiao Sun, Jinhua Zhang, Johnny Yang, Changlin Li, Yongchun Shen.

Registration fee:

Free for SAPA-NE members, unemployed, MIT and Harvard students.

\$10 for all other participants.

For more information, please visit our website:

<http://www.sapa-neweb.org>

Program

1:00-1:30 PM	Registration and Job Fair
1:30-2:10 PM	Michele Maher Director of staffing, Human resource, Novartis Institute for Biomedical Research, Inc.
2:10-2:40 PM	Devyn Smith, Ph.D. Principal, The Frankel Group LLC
2:40-3:10 PM	Jiahong Juda, MD BurnBright Partners
3:10-3:30 PM	Break/Net-working
3:30-4:00 PM	Shannon Murphy Sr. Staffing Specialist, Human Resources, Millennium: The Takeda Oncology Company
4:00-4:30 PM	John Zhanag, Ph.D. CEO, Systems Analytics
4:30-5:00 PM	Ken Li, Msc, MBA Chiral Quest
5:00-6:30 PM	Reception/networking

Saturday, Feb 28, 2009

Where: Tang Center (E51-335), MIT Sloan School of Management

Street Address: 70 Memorial Drive, Cambridge, MA

Co-organizers: MIT Economics and Talent Forum



Sino-American Pharmaceutical Professionals
Association-
New England (SAPA-NE)

Career Development Symposium

Saturday, Feb 28, 2009
Tang Center , MIT Sloan Business School



美中医药开发协会纽英伦分会
Sino-American Pharmaceutical Professionals Association New England

Michele Maher

Michele Maher joined Novartis Institutes for BioMedical Research (NIBR) as Director of Staffing in December of 2006. As Head of US Staffing, Michele is account-

able for "Best in Class" Talent Acquisition strategies for Novartis Research. She is a steering committee member of the Novartis Cambridge Women's Resource Group and co-chair of the Networking sub-committee which is dedicated to providing learning opportunities through strengthening and building relationships with local scientific and management organizations.

Prior to Novartis, Michele spent five years at Genzyme Corporation where she was responsible for developing, mentoring, and leading a team of recruitment professionals supporting their Commercial, Research & Development organizations. Michele has more than fourteen years of staffing experience within the Biotechnology, Pharmaceutical, and High Technology industries and has been employed at companies such as at Therion Biologics, Vertex Pharmaceuticals, and Sun Microsystems. Michele holds an MBA from Simmons School of Management in Boston and a Bachelor's degree in Communications from the University of Massachusetts at Amherst.



John Zhang

Dr. John Zhang is currently a Founder and President of Systems Analytics. The company develops and applies data mining and pattern recognition software for the analysis of biological data. The software has been used by biotech and pharmaceutical companies, environmental conscious organizations, and healthcare industry to identify accurate and robust biomarkers for various consultant for Earth Technology Corp. (now part of Tyco Corp.).

Dr. Zhang received a Ph.D. in Mechanical Engineering from MIT, an M.S. from Beijing University, and a B.S. from Zhejiang University. He is a licensed professional engineer.



Shannon Murphy

Shannon Murphy has been a pharmaceutical and biotech recruiter in the Cambridge area for 13 years. Starting her career, she headed up the Scientific and Clinical divisions of a nationally recognized staffing company in Burlington MA. Shannon currently works for Millennium: The Takeda Oncology Company in Cambridge MA, where she has been an in-house senior recruiter for 5 years. Shannon is responsible for the Discovery and Development Divisions at Millennium.



Devyn Smith

Devyn has been at The Frankel Group since January, 2003. He has had a wide range of experiences, across multiple therapeutic areas, including pulmonology, infectious disease, diabetes/metabolic, neurology, psychiatry, cardiovascular, dermatology, rheumatology, hematology, and immunology. During his time at The Frankel Group, he has had the opportunity to investigate a host of technology platforms, including basic R&D tools, cell based therapies, RNA silencing, and macromolecules/biologic products. Client relationships have ranged from large pharma to small biotech companies.

While at The Frankel Group, Devyn has had a diverse range of experiences with clients including: (1) developing an analytical tool for the assessment and selection of strategically important indications and technologies for a large biotechnology company which has been deployed in more than 30 different engagements, (2) performing an assessment of technology platforms for an immunology franchise, as well as the scoring and ranking of platform technologies to enable in-licensing business development efforts of a biotechnology company, (3) performing multiple market assessments of various diseases that were incorporated into a cohesive franchise strategy for several large pharmaceutical companies, and (4) assessing the market opportunity and specific market segments for a novel medical device to assist a medical device company in making a go-no go decision.

Prior to joining The Frankel Group, Devyn was at Adventis Corporation working as a management consultant to clients in information intensive companies. Prior to this experience, he completed a PhD at Harvard Medical School in Genetics. His research focused on embryonic development and retroviral technologies for gene transfer in vertebrates. His research culminated in 12 publications in leading journals such as Cell, Nature, and Development. He also holds an MS from Idaho State University in Developmental Biology and a BS in Zoology and Chemistry from Brigham Young University.



Jiahong Juda

Dr. Jiahong Juda is an executive coach with official training in physics and a passion for unlocking the hidden potential in the world around her. Acting on her passion, she founded BurnBright Partners, a company that works with traditionally successful executives. She helps them "defog" in taking their success to the next level, eliminate professional and personal roadblocks, and enhance capability of accessing their potential.

Born in China in the late 50s, Dr Jiahong Juda has a wide range of professional experiences in business, research institutions, and non-profits, and made many career transitions. She co-founded WEST (Women Entrepreneurs in Science and Technology) in 2000. She is a member of the Board of Directors at Speech Technology and Applied Research Corp., and a member of the Society for organizational Learning, Organizational Development Learning Group, and the New England Society of Applied Psychology.



Ken Li

Ken has extensive experience on the chemical process development, management, sales/marketing, finance and social networking in both US and China. Ken is now back to US Chiral Quest headquarter taking in charge of marketing and sales after working as general manager of Chiral Quest (China) for near three years focusing on the development and commercializing of Chiral drug intermediates and/or Active Pharmaceutical Ingredient (API) with Chiral Quest's proprietary technology. Mr. Li managed the operations of the 40,000 sqf R&D lab in Jianshan and build up Chiral Quest (Suzhou) from ground to a 240,000 sqf pilot facility with 130m Yuan investment. Under Ken's leadership, Chiral Quest (China) delivered hundreds of projects up to several hundred kilo batches to the customers, built up the team from 8 to 70 employee; received government grant from Suzhou Industrial Park, Suzhou City and Jiangshu province; the company was recognized as: The Most Promising Company at ChinaBio2007 conference and received Gold Key award from Suzhou Industrial Park in 2007. Mr. Li was instrumental for closing Chiral Quest's \$13M series A finance in '08, and \$5m Management Buyout (MBO) from its US public parent company VioQuest (Tick: VQPH) in '07. Prior join Chiral Quest, Mr Li was VP of operations for BioDefense Corp. at Boston in charge of the marketing/sales and product development of anti-bioterrorism product. Ken had over 10 years chemical process development experience for intermediates and API under cGMP from Eisai and Wyeth. Ken was the key chemical process developer for the \$80 million, 35 step synthesis of anti-sepsis new drug SGEA from the pre-clinical to the phase III clinical trial and completed several complex APIs process development. Ken had over 5 years import/export experience for the API and intermediates in China. Mr. Li received MBA from Babson - the #1 entrepreneurship program in US, and Msc from City College of New York in 1994. Ken is the director of the board of SAPA, and was the founding president of SAPA-NE, Ken received three times project accomplishment award from Eisai and 4 times Service Excellence Award from SAPA.